Chinese medicine （CM） pattern diagnosis （Bianzheng or syndrome differentiation）, as another patient classification approach, has been incorporated with biomedicine diagnosis in clinical practice in China, and the ...Chinese medicine （CM） pattern diagnosis （Bianzheng or syndrome differentiation）, as another patient classification approach, has been incorporated with biomedicine diagnosis in clinical practice in China, and the clinical experience has proven that the integration of biomedicine and CM is better in the treatment of many diseases. CM pattern diagnosis is completely different from the diagnosis in biomedicine, and it must take an active role in innovation for medical sciences. This paper is trying to discuss how CM pattern diagnosis lead to innovations in basic research, clinical research and new drug discovery. Scientific basis of CM pattern in innovation of basic research, clinical efficacy and safety, CM pattern based clinical trial design, CM pattern and clinical practice guideline in innovation of clinical study, CM pattern based indication finding, and CM pattern based network pharmacology in innovation of new drug discovery have been discussed.展开更多
基金Supported by the National Tenth Five Year Plan Project of China(No.90209002)National Natural Science Foundation of China(No.90709007 and 30825047)
文摘Chinese medicine （CM） pattern diagnosis （Bianzheng or syndrome differentiation）, as another patient classification approach, has been incorporated with biomedicine diagnosis in clinical practice in China, and the clinical experience has proven that the integration of biomedicine and CM is better in the treatment of many diseases. CM pattern diagnosis is completely different from the diagnosis in biomedicine, and it must take an active role in innovation for medical sciences. This paper is trying to discuss how CM pattern diagnosis lead to innovations in basic research, clinical research and new drug discovery. Scientific basis of CM pattern in innovation of basic research, clinical efficacy and safety, CM pattern based clinical trial design, CM pattern and clinical practice guideline in innovation of clinical study, CM pattern based indication finding, and CM pattern based network pharmacology in innovation of new drug discovery have been discussed.
文摘目的观察来氟米特(leflunomide,LEF)治疗中医不同证型类风湿关节炎(rheumatoid arthritis,RA)的疗效有无差异。方法选取150例类风湿关节炎患者,按照中医辨证标准分为湿热痹阻证、寒湿痹阻证、肾气虚寒证、肝肾阴虚证、瘀血痹阻证5个证型组,应用LEF口服治疗,疗程3个月,观察LEF治疗前后压痛关节数、肿胀关节数、晨僵时间、患者疼痛评分(visual analog scale,VAS)、类风湿因子(rheumatoid factor,RF)、血沉(erthrocyte sedimentation rate,ESR)、C-反应蛋白(C-reactive protein , CRP)、美国风湿病协会标准 20% 改善 (American College of Rheumatology 20% improvement , ACR20)、美国风湿病协会标准50%改善(American College of Rheumatology 50% improvement , ACR50 )等指标的变化,进行统计分析。结果与本组治疗前比较,各组治疗后压痛关节数、肿胀关节数均减少,VAS、ESR、CRP、RF均降低,差异有统计学意义(P<0.05);除肾气虚寒证、肝肾阴虚证外,其余各组关节晨僵时间均缩短,差异有统计学意义(P<0.05)。其中湿热痹阻、寒湿痹阻、瘀血痹阻证型治疗后压痛关节数、肿胀关节数、晨僵时间、VAS 、RF改变及总有效率改善明显优于肾气虚寒证和肝肾阴虚证,差异有统计学意义(P<0.05)。结论 LEF治疗RA疗效显著,其中湿热痹阻证、寒湿痹阻证、瘀血痹阻证效果明显优于肝肾阴虚证和肾气虚寒证。
